Pharmacopsychiatry
DOI: 10.1055/a-0975-9595
Review
© Georg Thieme Verlag KG Stuttgart · New York

Clinical Utilization of Pharmacogenetics in Psychiatry – Perspectives of Pharmacists, Genetic Counselors, Implementation Science, Clinicians, and Industry

Lisa Brown
1  Myriad Neuroscience, Myriad Genetics Inc, Salt Lake City, United States
,
Seenae Eum
2  Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, United States
,
Susanne B. Haga
3  Duke University School of Medicine, Durham, United States
,
Jeffrey R. Strawn
4  Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati, Cincinnati, United States
,
Heather Zierhut
2  Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, United States
› Author Affiliations
Further Information

Publication History

received 01 April 2019
revised 02 July 2019

accepted 09 July 2019

Publication Date:
11 September 2019 (online)

Abstract

Introduction The use of pharmacogenomic (PGx) testing to guide decisions and improve patient outcomes has increased in recent years. PGx testing represents a decision support tool that may inform dosing, increase the likelihood of treatment response, and identify patients at risk for medication side effects.

Methods This is a narrative review of utilization of PGx testing in psychiatry from stakeholders including, pharmacists, genetic counselors, implementation scientists, industry, and clinicians.

Results While many limitations exist to streamline use of PGx testing in psychiatry, various stakeholders are crucial to clinical implementation.

Discussion PGx testing can assist in medication selection and improve patient outcomes; however, more data are needed to understand when and how to incorporate PGx testing into psychiatric practice.